Lexeo Therapeutics Inc (LXEO) 13F Holders & Ownership Data (145 Funds, Q2 2026)

LXEO ranks #3759 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

145 institutions disclose a position in LXEO, but none treat it as a major bet — even Affinity Asset Advisors, LLC, its most concentrated holder, allocates just 1.2% of its own portfolio to it.

Qube Research & Technologies Ltd has added to its LXEO position for two straight quarters, increasing it by $5.1M to reach $6.4M today.

Paradigm Biocapital Advisors LP has trimmed its LXEO position for two straight quarters, cutting it by $27.9M while still holding $19.4M.

LXEO is up 1.7% today, and institutions have been net buyers of $59.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

LXEO reported a net loss of $100.0M in its latest fiscal year.

• Not yet profitable — net loss of $100.0M in the latest fiscal year
• Net income declined year over year, from -$98.3M to -$100.0M
• Operating cash flow was negative, using $98.6M in cash
• Current ratio of 11.21x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range